CAS Number: 74150-27-9 |  Standard: In-house / EP Standard

Pimobendan Canine API is a high-quality active pharmaceutical ingredient widely used in veterinary medicine for the treatment of canine heart disease, particularly congestive heart failure (CHF) associated with dilated cardiomyopathy (DCM) and degenerative mitral valve disease (DMVD). Its proven efficacy and safety have made it a cornerstone therapy in modern veterinary cardiology.

Applications in Canine Cardiology

Pimobendan belongs to the pharmacological class of inodilators, offering a dual mechanism of action that provides significant therapeutic benefits:

This combined action improves cardiac output while decreasing the heart's workload, making Pimobendan particularly effective in the long-term management of heart failure in dogs.

Clinical Benefits

For dogs suffering from heart disease, Pimobendan Canine API helps alleviate common symptoms of congestive heart failure, including:

▸ Persistent coughing

▸ Labored or rapid breathing

▸ Reduced exercise tolerance

▸ Fluid retention and fatigue

By improving heart performance and circulation, Pimobendan reduces pulmonary and systemic congestion, enhances oxygen delivery to tissues, and significantly improves clinical symptoms and overall quality of life.

Proven Safety and Efficacy

Extensive clinical studies have demonstrated that Pimobendan is both safe and effective for canine use. Research shows that dogs treated with Pimobendan often experience:

▸ Prolonged survival time

▸ Slower progression of heart failure

▸ Improved long-term cardiac function

Compared with conventional therapies alone, Pimobendan has become a trusted and widely prescribed treatment for canine heart disease worldwide.

Our Strengths